Eagle Delays Third Quarter 2023 Results and Conference Call
09 November 2023 - 1:30PM
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the
“Company”) today announced that it will be delaying the release of
its third quarter 2023 results and investor conference call,
previously scheduled for today, Thursday, November 9, 2023. The
Company currently anticipates filing
a Form 12b-25, Notification of Late Filing,
with the Securities and Exchange Commission no later than one
business day after the due date of its Quarterly Report on
Form 10-Q for the third quarter ended September 30, 2023 (the
“Form 10-Q"), and expects to file its Form 10-Q by November 14,
2023, prior to the expiration of the extension period provided by
Rule 12b-25 under the Securities Exchange Act of 1934.
The Company requires more time to review potential adjustments
relating to the reporting of sales of PEMFEXY® prior to filing its
Form 10-Q. In addition, the Company expects to revise its
previously disclosed 2023 full year guidance downward.
“We remain confident in the strength of our business and our
outlook for 2024, and we look forward to reporting on our
commercial portfolio, progress on our pipeline and other
initiatives,” stated Scott Tarriff, President and CEO of Eagle.
Third Quarter Fiscal Year 2023 Earnings Conference
Call
The Company will reschedule its third quarter 2023 financial
results call at a time to be announced.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research
and development, clinical, manufacturing and commercial expertise.
Eagle is committed to developing innovative medicines that result
in meaningful improvements in patients’ lives. Eagle’s
commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®,
BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through
its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and
CNS/metabolic critical care pipeline includes product candidates
with the potential to address underserved therapeutic areas across
multiple disease states, and the company is focused on developing
medicines with the potential to become part of the personalized
medicine paradigm in cancer care. Additional information is
available on Eagle’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, and other securities law. Forward-looking
statements are statements that are not historical facts. Words and
phrases such as “anticipated,” “forward,” “will,” “would,” “could,”
“may,” “remain,” “potential,” “prepare,” “expected,” “believe,”
“plan,” “near future,” “belief,” “guidance,” and similar
expressions are intended to identify forward-looking statements.
These statements include, but are not limited to, the Company’s
expectations with respect to the timing of its SEC filings,
including the Form 12b-25 and the Form 10-Q, and the anticipated
release of financial results for the third quarter ended September
30, 2023, expectations with respect to the anticipated reporting of
financial and business results, including
potential adjustments related to the reporting of sales
for PEMFEXY®, and statements and expectations regarding the
Company’s financial projections and guidance, including anticipated
financial performance for 2023, the strength of the Company’s
business, pipeline and other initiatives and the potential of the
Company’s pipeline and product candidates to address underserved
therapeutic areas across multiple disease states. All of such
statements are subject to certain risks and uncertainties, many of
which are difficult to predict and generally beyond the Company’s
control, that could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. Such risks and uncertainties include,
but are not limited to: the impacts of the post- COVID-19
environment and geopolitical factors such as the conflicts between
Russia and Ukraine and Gaza and Israel; delay in or failure to
obtain regulatory approval of the Company's or its partners’
product candidates and successful compliance with FDA, European
Medicines Agency and other governmental regulations applicable to
product approvals; changes in the regulatory environment; the
uncertainties and timing of the regulatory approval process;
whether the Company can successfully market and commercialize its
product candidates; the success of the Company's relationships with
its partners; the outcome of litigation involving any of its
products or that may have an impact on any of its products; the
strength and enforceability of the Company’s intellectual property
rights or the rights of third parties; competition from other
pharmaceutical and biotechnology companies and the potential for
competition from generic entrants into the market; unexpected
safety or efficacy data observed during clinical trials; clinical
trial site activation or enrollment rates that are lower than
expected; the risks inherent in drug development and in conducting
clinical trials; risks inherent in estimates or judgments relating
to the Company’s critical accounting policies, or any of the
Company’s estimates or projections, which may prove to be
inaccurate; unanticipated factors in addition to the foregoing that
may impact the Company’s financial and business projections and
guidance and may cause the Company’s actual results and outcomes to
materially differ from its projections and guidance; and those
risks and uncertainties identified in the “Risk Factors” sections
of the Company's Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the Securities and Exchange
Commission (the “SEC”) on March 23, 2023, the Company’s Quarterly
Reports on Form 10-Q for the quarter ended March 31, 2023, filed
with the SEC on May 9, 2023, and for the quarter ended June 30,
2023, filed with the SEC on August 8, 2023, and its other
subsequent filings with the SEC. Readers are cautioned not to place
undue reliance on these forward-looking statements. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, the Company undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Investor Relations for Eagle Pharmaceuticals,
Inc.:
Lisa M.
Wilson In-Site
Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com
Public Relations for Eagle Pharmaceuticals,
Inc.:Faith Pomeroy-WardT: 817-807-8044E:
faith@eagleus.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024